EG 427 has released encouraging first clinical data from its experimental DNA medicine EG110A, showing major benefits for patients with neurogenic bladder linked to spinal cord injury.

In the ongoing Phase 1b/2a study, the lowest dose of EG110A cut urinary incontinence episodes by more than 88% after 12 weeks of treatment. Improvements were visible from week 4, and the therapy has so far shown good tolerability with no systemic side effects.

Cornelia Haag-Molkenteller, chief medical officer at EG 427, said: “These initial clinical results showing a significant reduction in the number of incontinence episodes at the lowest dose are truly remarkable. Although we are still early in the clinical development, for patients living with neurogenic detrusor overactivity who struggle with frequent, unpredictable urinary incontinence, we believe EG110A could represent a medical breakthrough.”

EG110A is based on a non-replicating HSV-1 vector designed to selectively silence type C sensory neurons that drive bladder muscle overactivity. Unlike existing therapies, the treatment aims to act locally while preserving other bladder functions.

The trial (NCT06596291) is enrolling 16 adults with neurogenic detrusor overactivity following spinal cord injury who have not responded to standard care. Participants receive a single course of intradetrusor injections at clinical sites in California, Michigan, Pennsylvania and Texas.

Philippe Chambon, chief executive of EG 427, said: “For EG 427, these results validate a biological mechanism underpinning multiple diseases driven by type C sensory neuron activity. We can now envision developing EG110A more broadly in clinical studies, including in the pain field.”

Neurogenic detrusor overactivity is a common bladder dysfunction in patients with spinal cord injury, multiple sclerosis and Parkinson’s disease. It can cause uncontrolled incontinence, kidney damage and infections that can be fatal in up to 10% of cases. The condition affects more than 2 million people across major markets.

The latest data will be presented at the Cell & Gene Meeting on the Mesa on October 7 in Phoenix, Arizona.